Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells

Chimeric antigen receptor (CAR) T-cell therapy is a promising therapeutic strategy against lymphoma. However, post-treatment relapses due to antigen loss remain a challenge. Here the authors designed a novel bicistronic CAR construct and tested its functions in vitro and in vivo. The CAR construct c...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cytotherapy (Oxford, England) England), 2021-08, Vol.23 (8), p.715-723
Hauptverfasser:	Wang, Ying, Zhong, Kailun, Ke, Jun, Chen, Xi, Chen, Yi, Shu, Wangyun, Chen, Chunhuan, Hu, Shan, Sun, Xiaoke, Huang, Haibin, Luo, Chong, Liu, Lifang, Yang, Jiaming, Zhang, Yongke, Zhi, Huijun
Format:	Artikel
Sprache:	eng
Schlagworte:	4-1BB bispecific CAR T cell CD19 CD20 co-stimulatory domains ICOS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!